Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
899 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03066648 | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | completed | Phase 1 | 241 | Novartis PharmaceuticalsINDUSTRY | 8 | May 18, 2025 | clinicaltrials |
| NCT01526369 | A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer(TH V THL) | completed | Phase 3 | 75 | Cancer Trials IrelandNETWORK | 8 | May 9, 2025 |
| NCT03551626 | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes(COMBI-APlus) | completed | Phase 3 | 552 | Novartis PharmaceuticalsINDUSTRY | 23 | Apr 29, 2025 | clinicaltrials |
| NCT02388906 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma(CheckMate 238) | completed | Phase 3 | 906 | Bristol-Myers SquibbINDUSTRY | 25 | Apr 24, 2025 | clinicaltrials |
| NCT03110107 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 376 | Bristol-Myers SquibbINDUSTRY | 17 | Apr 24, 2025 | clinicaltrials |
| NCT04232241 | Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | active not recruiting | Phase 2 | 167 | Universitätsklinikum Hamburg-EppendorfOTHER | 7 | Apr 22, 2025 | clinicaltrials |
| NCT03464045 | Empa PASS on Urinary Tract Malignancies | completed | — | 344,995 | Boehringer IngelheimINDUSTRY | 3 | Apr 20, 2025 | clinicaltrials |
| NCT03423303 | A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)(ProScreen) | enrolling by invitation | N/A | 17,400 | Tampere UniversityOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06931184 | Self- Sampling in Cervical Cancer Routine Screening(FALCON) | enrolling by invitation | N/A | 40,000 | Tampere University HospitalOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06551857 | The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Hearing-Related Quality of Life(CaSPiN) | recruiting | — | 250 | Turku University HospitalOTHER_GOV | 1 | Apr 16, 2025 | clinicaltrials |
| NCT03353831 | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | completed | Phase 3 | 574 | AGO Research GmbHINDUSTRY | 12 | Apr 6, 2025 | clinicaltrials |
| NCT03376672 | Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients | active not recruiting | Phase 2 | 120 | Raija SilvennoinenOTHER | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03733990 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | completed | Phase 1 / Phase 2 | 216 | Faron Pharmaceuticals LtdINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT03173560 | Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma | completed | Phase 2 | 343 | Eisai Inc.INDUSTRY | 16 | Apr 1, 2025 | clinicaltrials |
| NCT03635983 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | completed | Phase 3 | 783 | Bristol-Myers SquibbINDUSTRY | 27 | Apr 1, 2025 | clinicaltrials |
| NCT02312960 | Radium-223 Dichloride Long-term Follow-up Program | completed | Phase 4 | 255 | BayerINDUSTRY | 22 | Mar 25, 2025 | clinicaltrials |
| NCT06078514 | Sexual Function and Quality of Life After LEEP: a Prospective Multi-Center Study(SEQUEL) | recruiting | — | 1,000 | Tampere University HospitalOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT02492711 | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer(SOPHIA) | completed | Phase 3 | 624 | MacroGenicsINDUSTRY | 18 | Mar 17, 2025 | clinicaltrials |
| NCT04668781 | Improvement of Care of Patients Undergoing Pancreaticoduodenectomy | completed | N/A | 92 | Helsinki University Central HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT02413736 | Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST | active not recruiting | Phase 3 | 255 | Heikki JoensuuOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT01958021 | Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer(MONALEESA-2) | completed | Phase 3 | 668 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
| NCT06850545 | Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer(KuPSMALu) | recruiting | — | 150 | Kuopio University HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04186819 | Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer. | completed | Phase 3 | 356 | Blue Earth DiagnosticsINDUSTRY | 4 | Feb 26, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT05917860 | Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer(NeoADT-TULSA) | active not recruiting | Phase 1 | 15 | Turku University HospitalOTHER_GOV | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04731558 | Pre- Vs Postoperative Thromboprophylaxis for Liver Resection(PREPOSTEROUS) | recruiting | Phase 4 | 1,012 | Helsinki University Central HospitalOTHER | 2 | Feb 14, 2025 | clinicaltrials |
| NCT05245877 | Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery(PREPOSTEROUS2) | recruiting | Phase 4 | 800 | Helsinki University Central HospitalOTHER | 3 | Feb 14, 2025 | clinicaltrials |
| NCT02625441 | Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer(BOLD-1) | active not recruiting | Phase 3 | 516 | Helsinki University Central HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | completed | Phase 3 | 1,209 | Janssen Research & Development, LLCINDUSTRY | 33 | Feb 4, 2025 | clinicaltrials |
| NCT01855750 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 838 | Janssen Research & Development, LLCINDUSTRY | 27 | Feb 4, 2025 | clinicaltrials |
| NCT05257850 | Management of Breathlessness with High-flow Nasal Therapy or a Fan | completed | N/A | 36 | Tampere University HospitalOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT05328115 | A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease | completed | Phase 1 | 33 | Alzinova ABINDUSTRY | 1 | Jan 31, 2025 | clinicaltrials |
| NCT03495960 | Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System(FIORELLA) | completed | Phase 2 | 72 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Jan 30, 2025 | clinicaltrials |
| NCT02149030 | Effectiveness of Cervical Screening in HPV Vaccinated Women(HPV-004) | active not recruiting | N/A | 6,958 | Tampere UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04846933 | Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC(DECIDER) | recruiting | N/A | 200 | Turku University HospitalOTHER_GOV | 1 | Jan 16, 2025 | clinicaltrials |
| NCT04755517 | Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)(HPV400) | enrolling by invitation | N/A | 14,000 | Tampere University HospitalOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer(CheckMate 7FL) | completed | Phase 3 | 521 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 8, 2025 | clinicaltrials |
| NCT06755619 | CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)(CAPCI) | recruiting | — | 60 | Nordic Lymphoma GroupNETWORK | 1 | Jan 1, 2025 | clinicaltrials |
| NCT01928394 | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 1,163 | Bristol-Myers SquibbINDUSTRY | 8 | Dec 27, 2024 | clinicaltrials |
| NCT03484702 | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma(TRANSCENDWORLD) | completed | Phase 2 | 113 | CelgeneINDUSTRY | 11 | Dec 27, 2024 | clinicaltrials |
| NCT05477589 | Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML(SCRIPT-AML) | recruiting | Phase 3 | 170 | Vastra Gotaland RegionOTHER_GOV | 10 | Dec 19, 2024 | clinicaltrials |
| NCT06740097 | Feasibility of Aspirate Tissue Monitoring in Neuro-oncological Surgery(ATM GBM INT) | recruiting | N/A | 50 | Kuopio University HospitalOTHER | 2 | Dec 18, 2024 | clinicaltrials |
| NCT04027309 | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy(HOVON 156 AML) | active not recruiting | Phase 3 | 777 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 13 | Dec 17, 2024 | clinicaltrials |
| NCT06736470 | Surgical Suction Aspirates Fluorescence Measurement(ATM GBM) | recruiting | — | 25 | Kuopio University HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT01531595 | Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer(AXOAXI) | active not recruiting | Phase 2 | 100 | Pia OsterlundOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04260269 | Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study(CardioSwitch) | enrolling by invitation | — | 200 | Helsinki University Central HospitalOTHER | 7 | Dec 12, 2024 | clinicaltrials |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-4) | terminated | Phase 3 | 551 | BayerINDUSTRY | 35 | Dec 11, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials